Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The vitamin K-dependent clotting pathway involves a group of coagulation factors (II, VII, IX, X) and regulatory proteins (Protein C, S, Z) that require vitamin K for gamma-carboxylation of glutamate residues. This modification is crucial for calcium binding and membrane interaction, essential steps in the coagulation cascade. Dysfunction in this pathway can lead to bleeding or thrombotic disorders. Warfarin inhibits this pathway via inhibition of VKORC1.
Inhibition of vitamin K epoxide reductase (VKORC1) leading to decreased synthesis of functional clotting factors.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vitamin K-dependent Clotting Pathway (VKDCP).